{"title":"Case report: Milk oral immunotherapy for adult-onset cow's milk-induced anaphylaxis.","authors":"Jae-Hyuk Jang, Sooyoung Lee, Young-Min Ye","doi":"10.5415/apallergy.0000000000000218","DOIUrl":null,"url":null,"abstract":"<p><p>While food allergies affect individuals across all age groups, oral immunotherapy (OIT) has been widely studied and implemented in pediatric populations. Here, we report a successful case of cow's milk (CM) OIT in a 60-year-old male with adult-onset cow milk allergy. The patient who was previously tolerated with CM initially presented with generalized pruritus, rash, dyspnea, urticaria, and dizziness occurring 4 hours after consuming milk-containing foods. The patient was positive on the skin prick test and for specific IgEs to milk (24.4 kU/L) and casein (31.2 kU/L). After diagnosis, CM OIT was initiated using bread containing milk protein. The protocol began with a 1/4 slice of milk bread (1.55 g of milk protein) and gradually increased to 1 full slice (6.2 g of milk protein) over the course of 4 years. Throughout the period, the patient's immunological markers consistently improved, with his CM-specific IgE level decreasing from 24.40 to 1.50 kU/L and his casein-specific IgE level decreasing from 31.20 to 2.24 kU/L. The patient successfully completed an oral food challenge with 190 mL of cow milk and currently maintains a daily consumption of 200 mL of CM without adverse reactions. This case demonstrates that CM OIT can be successfully implemented in elderly patients with adult-onset CM allergy. The clinical and immunological responses suggest that immune modulation remains possible even in older adults, suggesting potential therapeutic options for adult-onset food allergies.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 4","pages":"343-345"},"PeriodicalIF":2.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12672181/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.0000000000000218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
While food allergies affect individuals across all age groups, oral immunotherapy (OIT) has been widely studied and implemented in pediatric populations. Here, we report a successful case of cow's milk (CM) OIT in a 60-year-old male with adult-onset cow milk allergy. The patient who was previously tolerated with CM initially presented with generalized pruritus, rash, dyspnea, urticaria, and dizziness occurring 4 hours after consuming milk-containing foods. The patient was positive on the skin prick test and for specific IgEs to milk (24.4 kU/L) and casein (31.2 kU/L). After diagnosis, CM OIT was initiated using bread containing milk protein. The protocol began with a 1/4 slice of milk bread (1.55 g of milk protein) and gradually increased to 1 full slice (6.2 g of milk protein) over the course of 4 years. Throughout the period, the patient's immunological markers consistently improved, with his CM-specific IgE level decreasing from 24.40 to 1.50 kU/L and his casein-specific IgE level decreasing from 31.20 to 2.24 kU/L. The patient successfully completed an oral food challenge with 190 mL of cow milk and currently maintains a daily consumption of 200 mL of CM without adverse reactions. This case demonstrates that CM OIT can be successfully implemented in elderly patients with adult-onset CM allergy. The clinical and immunological responses suggest that immune modulation remains possible even in older adults, suggesting potential therapeutic options for adult-onset food allergies.
期刊介绍:
Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.